RT期刊文章SR电子T1特征和治疗方案跨ERS尖锐严重的哮喘注册机构JF欧洲呼吸杂志JO EUR RESSIR J FD欧洲呼吸学会SP 1901163 DO 10.1183/13993003.01163-2019 VO 55 IS 1 A1 VAN BRAGT，JOB J.M.M.H.188bet官网地址A1 Adcock，Ian M. A1 Bel，Elisabeth H.D.A1 Braunstahl，Gert-Jan A1 Ten Brinke，Anneke A1 Busby，John A1 Canonica，Giorgio W. A1 Cao，Hui A1 Chung，Kian Fan A1 CSOMA，ZSUZSANNA A1 DAHLUN，BARBRO A1 DAVIN，BARBRO A1 DAVIN，ELIZABETH A1 HANSANNESNE，SUSANNE，SUSANNE A1 HEFFLERA1 Horvath, Ildiko A1 Korn, Stephanie A1 Kots, Maxim A1 Kuna, Piotr A1 Kwon, Namhee A1 Louis, Renaud A1 Plaza, Vicente A1 Porsbjerg, Celeste A1 Ramos-Barbon, David A1 Richards, Levi B. A1 Škrgat, Sabina A1 Sont，Jacob K. A1 Vijverberg，Susanne J.H.A1 Weersink，Els J.M. A1 Yasinska，Valentyna A1 Wagers，Scott S. A1 Djukanovic，Ratko A1 Maitland-Van der Zee，Anke H.摘要AB对整个欧洲严重哮喘患者的特征和治疗知之甚少，但两者都可能有所不同。这是欧洲呼吸学会的首次研究，严重的异质性哮喘研究合作，以患者为188bet官网地址中心（SHARP）临床研究合作，旨在探索这些变化。因此，我们的目的是在开始生物学之前比较欧洲严重的哮喘注册表和治疗中患者的特征。这是对11个国家严重哮喘注册处的汇总数据的横截面回顾性分析，该数据与已建立的患者数据库一起加入了Sharp。患者在特征和生活方式因素方面表现出许多差异。目前的吸烟者的范围从0％（波兰和瑞典）到9.5％（比利时），平均体重指数范围从26.2（意大利）到30.6 kg·M-2（英国），均值均值差异是均值前强骨前递增的均值差异预测的1 s％的体积为20.9％（荷兰与匈牙利）。 Before starting biologicals patients were treated differently between countries: mean inhaled corticosteroid dose ranged from 700 to 1335 µg·day−1 between those from Slovenia versus Poland when starting anti-interleukin (IL)-5 antibody and from 772 to 1344 µg·day−1 in those starting anti-IgE (Slovenia versus Spain). Maintenance oral corticosteroid use ranged from 21.0% (Belgium) to 63.0% (Sweden) and from 9.1% (Denmark) to 56.1% (the UK) in patients starting anti-IL-5 and anti-IgE, respectively.The severe asthmatic population in Europe is heterogeneous and differs in both clinical characteristics and treatment, often appearing not to comply with the current European Respiratory Society/American Thoracic Society guidelines definition of severe asthma. Treatment regimens before starting biologicals were different from inclusion criteria in clinical trials and varied between countries.The severe asthma population in Europe is heterogeneous and differs in clinical characteristics and treatment. Harmonisation across registries and guidelines is needed and requires collection of same data across cohorts to enable future research in SHARP. http://bit.ly/2krxHPf